The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions [0.03%]
蝴蝶展翅——PAPILLON研究：化疗序贯艾伏明塔姆单药治疗EGFR 20号外显子插入突变非小细胞肺癌患者疗效的探索性分析
Dalia Kaakour,Misako Nagasaka
Dalia Kaakour
Epidermal growth factor receptor (EGFR) exon 20 insertions are a rare subtype of EGFR mutations that do not respond to EGFR tyrosine kinase inhibitors developed for sensitizing mutations. In 2021, two drugs, amivantamab and mobocertinib eac...
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? [0.03%]
玛丽波莎：对于一线治疗，Amivantamab和Lazertinib能否取代Osimertinib？
Danielle Brazel,Misako Nagasaka
Danielle Brazel
Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations. Amivantamab is a bispecific antibody against EGFR and MET alterations. Lazertinib is a tyrosi...
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study [0.03%]
阿帕替尼联合PD-1抗体治疗免疫经治晚期非小细胞肺癌的疗效和安全性：回顾性探索研究
Xue-Jun Dou,Run-Yang Ma,De-Wang Ren et al.
Xue-Jun Dou et al.
Objective: This study aimed to investigate the effectiveness and tolerability of anlotinib plus PD-1 blockades in patients with previously immunotherapy treated advanced non-small-cell lung cancer (NSCLC). ...
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver [0.03%]
克服中心β-片层#6 (Cβ6) ALK突变（L1256F）、TP53突变以及EML4-ALK v3/b和v5a/b剪接变异体的短形式是重新构想的第五代(5G) ALK TKI必须达到的未满足需求
Alexandria T M Lee,Sai-Hong Ignatius Ou
Alexandria T M Lee
Despite the development and approval of seven anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) spanning over three "generations" since the discovery of ALK fusion positive (ALK+) non-small cell lung cancer (NSCLC), there r...
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach [0.03%]
Lu氏方法在视频辅助胸腔镜手术中的创新技术
Baofeng Wang,Jiang Wang,Tongyu Sun et al.
Baofeng Wang et al.
Purpose: Lu's approach for video-assisted thoracoscopic surgery (LVATS), which derives from Uniportal Video-Assisted Thoracoscopic Surgery(UVATS), is a novel surgical approach for VATS and carries out micro-innovation for...
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact [0.03%]
最后一根稻草？：分析KEYNOTE-789临床试验的影响
Zhaohui Liao Arter,Misako Nagasaka
Zhaohui Liao Arter
Targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), have revolutionized the treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC). However, the emergence of resistance to E...
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? [0.03%]
ⅠB~ⅢA期NSCLC完全切除术后单用帕博利珠单抗辅助治疗适应证的解读：FDA批准PEARLS/KEYNOTE-091研究方案吗？
Misako Nagasaka,Saihong Ignatius Ou
Misako Nagasaka
One of the most recent advancements in NSCLC was the approval of immunotherapy in the adjuvant setting. Both atezolizumab and pembrolizumab have been approved for the use in early stage NSCLC patients post resection. As it broadens the opti...
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer [0.03%]
晚期非小细胞肺癌肿瘤相关中性粒细胞的单细胞测序分析
Jinpeng Shi,Jiayu Li,Haowei Wang et al.
Jinpeng Shi et al.
Purpose: Neutrophils act as a non-negligible regulator in the initiation and progression of malignancies, playing bifacial roles in the process. Thus, to understand the heterogeneity of tumor-associated neutrophils (TANs)...
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib [0.03%]
EGFR S645C和EGFR L858R共突变导致肺癌腺癌患者对奥希替尼产生原发耐药性
Li Wang,Fei Quan,Zhen Guo et al.
Li Wang et al.
Approximately 10-20% of patients demonstrate primary resistance to EGFR-TKIs, and different EGFR mutations vary in sensitivity to EGFR-TKIs. We report a case of a 78-year-old male with lung adenocarcinoma that EGFR L858R (AF = 1.32%) coexis...
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia [0.03%]
ALECTUS五年研究结果更新：阿来替尼600 mg Bid与lorlatinib相当（亚洲患者数据）
Alexandria T M Lee,Saihong Ignatius Ou
Alexandria T M Lee
Alectinib, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has demonstrated superior progression-free survival over crizotinib with both 300 mg twice daily (J-ALEX) or 600 mg twice daily (ALEX, ALESIA) do...